Cancer Therapy News and Research

RSS

Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has successfully completed enrollment and treatment of the last patient in its Phase I clinical trial of CUDC-101, Curis' first-in-class HDAC, EGFR and HER2 inhibitor.

3 May 2010

LifePoint Hospitals to acquire Sumner Regional Health Systems

LifePoint Hospitals, Inc., a leading hospital company focused on providing quality healthcare close to home in non-urban markets, today announced that the Company has agreed to purchase Sumner Regional Health Systems (SRHS), a comprehensive three-market hospital system serving 11 counties in the northern middle Tennessee region.

3 May 2010

Pfizer to maintain top spot in prescription sales through mergers and acquisitions

The rheumatoid arthritis treatment Humira will replace Lipitor as the world's biggest-selling drug in 2016, but a familiar name, Pfizer, will still be the biggest seller of medicines after the patent cliff according to the World Preview 2016 report published today by EvaluatePharma, the premier provider of pharma and biotech analysis.

3 May 2010

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

Monitoring of cell viability and toxicity are critical to many areas of biological and biomedical research. This is true for understanding the molecular and biochemical pathways regulating cell viability, for developing therapeutic agents which modulate cell viability and for identifying potential cytotoxic side effects of potential therapeutic agents.

3 May 2010

Researchers explore use of nanomedicine techniques for treatment of diseases in children

"Children are not small adults"—pediatricians say that's what makes their specialty different from the practice of medicine in adults. For similar reasons, researchers exploring the medical uses of nanotechnology believe that the use of molecular-level nanomedicine techniques in children will also require its own specialty.

3 May 2010

Leading experts deliver breast cancer updates at unique public forum

While significant advances have been made in breast cancer care, evidence has shown that Ontarians diagnosed with breast cancer continue to face considerable challenges with their needs for information, support and care. To respond to these needs, the Canadian Breast Cancer Foundation - Ontario Region is working with leaders in research, clinical care and community support to deliver current breast cancer information and education at a free public forum presented by Scotiabank Group in Barrie called Breast Cancer Today: An Evening of Care and Community.

30 Apr 2010

CTCA installs Calypso's real-time tumor tracking technology at Southwestern Regional Medical Center

Calypso Medical Technologies, Inc., a developer of non-ionizing real-time localization technology used for the precise tracking of tumor targets, and Cancer Treatment Centers of America, a national network of hospitals providing a comprehensive, fully integrative approach to cancer treatment, announced today that with the installation of the Calypso System at the CTCA at Southwestern Regional Medical Center in Tulsa, Okla., Calypso's real-time tumor tracking technology is now available at all CTCA centers nationwide.

30 Apr 2010

Approval of Provenge marks beginning of new era in cancer treatment: Dana-Farber Cancer Institute

Today's announcement that the U.S. Food and Drug Administration has approved Provengeâ, a new form of therapy for some prostate cancer patients, marks the beginning of an era in which patients' own immune systems become part of the standard therapeutic arsenal against cancer, say Dana-Farber Cancer Institute investigators who led a study of the treatment's effectiveness in patients.

30 Apr 2010

NWO awards 31 grants in Investment Subsidy NWO Medium programme

The Netherlands Organisation for Scientific Research (NWO) has awarded 31 grants in the Investment Subsidy NWO Medium programme for the acquisition of equipment, the setting up of data collections and the production of software and bibliographies. The total investment amounts to 10 million euro.

30 Apr 2010

IRX Therapeutics and Japan's NCRC collaborate to evaluate peptide-based cancer vaccines

IRX Therapeutics, a developer of novel immunomodulators to treat cancer and viral diseases, today announced that it has established a strategic collaboration with Japan's National Cancer Research Center (NCRC) to evaluate next-generation peptide-based cancer vaccines. Clinical research will be conducted at NCRC. IRX Therapeutics will provide its proprietary IRX-2 immunomodulatory regimen, clinical trial design and technical support. This is the first collaboration of its kind between the NCRC and a U.S.-based biotechnology firm.

30 Apr 2010

FDA approves new treatment option for prostate cancer

Today is an exciting day for men with advanced prostate cancer and the millions of families and loved ones who are profoundly affected. Today a new prostate cancer treatment option, Provenge, was approved by the Food and Drug Administration.

30 Apr 2010

Canadian researchers identify new therapeutic target for lung cancer

Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference in Geneva, highlights the exciting possibility that the molecule could soon become a new target for personalized cancer therapy.

30 Apr 2010

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that results from a pre-clinical study showed significant improvement in the delivery and half life of Å6, a proprietary peptide treatment for ovarian cancer currently in Phase 2 development by Angstrom Pharmaceuticals. Specifically, the incorporation of NexACT® enabled the dose of Å6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model.

29 Apr 2010

CINJ trial targets new combination therapy for advanced solid tumors

Building off recent laboratory discoveries relating to how cancer cells become resistant to therapies that attempt to starve cancer, scientists at The Cancer Institute of New Jersey (CINJ) are now applying that knowledge to a process in which cancer cells eat themselves to downsize and resist therapy. The ultimate goal of this effort is to improve upon current anticancer treatments.

29 Apr 2010

Physicists and oncologists to develop novel ultra sensitive platform for early cancer detection

The SPEDOC project will create the precursor to future devices for individualized diagnosis and monitoring of cancer therapy, which will allow the illness to be treated in earlier stages and at lower doses, reducing or preventing current secondary effects.

29 Apr 2010

New report evaluating use of SBRT in lung cancer treatment released

The American Society for Radiation Oncology has released its Emerging Technology Committee's report evaluating the use of stereotactic body radiotherapy in lung cancer treatment.

29 Apr 2010

Study: Curcumin nanoparticles limit toxicity of cancer therapy

Pre-treatment with curcumin, a component of the spice turmeric, makes ovarian cancer cells more vulnerable to chemotherapy and radiotherapy. Researchers writing in BioMed Central's open access Journal of Ovarian Research found that delivering the curcumin via very small (less than 100nm) nanoparticles enhanced the sensitizing effect.

29 Apr 2010

A new approach for treating neurological and degenerative disorders

In studies on cancer, heart disease, neurological disorders and other degenerative conditions, some scientists are moving away from the "nature versus nurture" debate, and are finding you're not a creature of either genetics or environment, but both - with enormous implications for a new approach to health.

29 Apr 2010

Three new biomarkers for ductal carcinoma in situ found

A new study of women who have been diagnosed with ductal carcinoma in situ (D.C.I.S.), may help personalize cancer treatment required by the women.

29 Apr 2010

Imaging costs for Medicare cancer patients on the rise

A study in the Journal of the American Medical Association analyzed data from Medicare cancer patients to determine the change in imaging use for this group.

29 Apr 2010

Cancer Therapy News and Research

Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor

LifePoint Hospitals to acquire Sumner Regional Health Systems

Pfizer to maintain top spot in prescription sales through mergers and acquisitions

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

Researchers explore use of nanomedicine techniques for treatment of diseases in children

Leading experts deliver breast cancer updates at unique public forum

CTCA installs Calypso's real-time tumor tracking technology at Southwestern Regional Medical Center

Approval of Provenge marks beginning of new era in cancer treatment: Dana-Farber Cancer Institute

NWO awards 31 grants in Investment Subsidy NWO Medium programme

IRX Therapeutics and Japan's NCRC collaborate to evaluate peptide-based cancer vaccines

FDA approves new treatment option for prostate cancer

Canadian researchers identify new therapeutic target for lung cancer

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

CINJ trial targets new combination therapy for advanced solid tumors

Physicists and oncologists to develop novel ultra sensitive platform for early cancer detection

New report evaluating use of SBRT in lung cancer treatment released

Study: Curcumin nanoparticles limit toxicity of cancer therapy

A new approach for treating neurological and degenerative disorders

Three new biomarkers for ductal carcinoma in situ found

Imaging costs for Medicare cancer patients on the rise

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News